AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) traded up 5.1% on Tuesday . The stock traded as high as $13.60 and last traded at $13.84. 154,661 shares were traded during trading, an increase of 18% from the average session volume of 131,241 shares. The stock had previously closed at $13.17.
Analyst Upgrades and Downgrades
AGMB has been the subject of a number of analyst reports. Cantor Fitzgerald initiated coverage on AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an “overweight” rating for the company. Piper Sandler initiated coverage on AgomAb Therapeutics in a report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target for the company. B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price objective for the company. HC Wainwright started coverage on AgomAb Therapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $35.00 target price for the company. Finally, Wall Street Zen cut shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, AgomAb Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $37.50.
Get Our Latest Stock Report on AGMB
AgomAb Therapeutics Stock Performance
AgomAb Therapeutics (NASDAQ:AGMB – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. As a group, analysts anticipate that AgomAb Therapeutics NV will post -1.76 earnings per share for the current fiscal year.
AgomAb Therapeutics Company Profile
AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.
AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.
See Also
- Five stocks we like better than AgomAb Therapeutics
- MongoDB’s Spending Fears Collide With a Much Stronger Growth Story
- With the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?
- Could IonQ Become More Than a Quantum Computing Company?
- Why China’s Memory Chip Breakthrough Won’t Crash the Market
Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
